(Q34031560)

30 July 2017

title

Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer (English)

1 reference

30 July 2017

1 reference

ChEBI release 2020-05-28

Ali McBride

1

1 reference

30 July 2017

Sara K Butler

series ordinal

2

1 reference

30 July 2017

publication date

1 May 2012

1 reference

American Journal of Health-System Pharmacy

30 July 2017

published in

1 reference

30 July 2017

volume

69

1 reference

30 July 2017

issue

9

1 reference

30 July 2017

page(s)

745-755

1 reference

Patterns of failure in a randomized trial of adjuvant chemotherapy in postmenopausal patients with early breast cancer treated with tamoxifen

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110237

Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110237

Expression of MRP1, LRP and Pgp in breast carcinoma patients treated with preoperative chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110237

Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110237

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110237

Natural products in cancer chemotherapy: past, present and future

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110237

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110237

Microtubules as a target for anticancer drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110237

A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110237

Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110237

Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110237

Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110237

Interaction of halichondrin B and homohalichondrin B with bovine brain tubulin

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110237

Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110237

Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110237

Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110237

A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110237

Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110237

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110237

Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110237

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110237

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110237

Peripheral neuropathy induced by microtubule-stabilizing agents.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110237

Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110237

31 March 2020

Identifiers

DOI

10.2146/AJHP110237

1 reference

30 July 2017

1 reference